Lonza to Acquire Exosomics Service Unit to Expand Exosomes Service Offering

Lonza to acquire Exosomics Service Unit in Siena, Italy to expand development service offering in exosome bioprocessing Expertise in exosomes isolation and characterization will drive innovation in this field Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutrition Mehr

Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration

Lonza to acquire and operate Codiak’s Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline Lonza and Codiak to establish a Center of Excellence focused on exosome manufacturing and characterization technologies Lonza to gain access to Mehr

Capital Markets Day 2021: Lonza to Capture Market Demand and Ensure Sustainable Value Creation Through Long-Term Growth

At its Capital Markets Day, Lonza outlined strategic priorities and innovation highlights with a clear focus on sustainable value creation Accelerated, de-risked, long-term investment program will drive sustainable business growth 2021 CAPEX anticipated at around 25% of sales, and remain Mehr

Lonza Invests to Expand Drug Product Development and Manufacturing Services in Switzerland

. Lonza will invest to expand its drug product manufacturing network in Switzerland The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel (CH) The expansion Mehr

Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform

. Triumvira’s T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza’s Cocoon® platform at the C3i Center Inc (C3i) in Montreal Transitioning to Lonza’s Cocoon® Platform enabled Triumvira to escalate development efforts and achieve IND approval in Mehr

Philippe Deecke appointed as Chief Financial Officer of Lonza Group

  Lonza appoints Philippe Deecke as CFO and member of the Lonza Group Executive Committee Philippe brings a wealth of experience from a 30-year career, which includes senior leadership roles in Novartis finance and time working as a McKinsey consultant Mehr

Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy

Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients Mehr

Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin

In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaborations to support COVID-19 programs including Mehr

Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply

. Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all elements Mehr

Lonza Completes Divestment of Specialty Ingredients Business

. Lonza announced today the completion of the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion. Albert M. Baehny, Chairman, Lonza commented: “Since announcing our intention Mehr